Drug combination therapy is expected to delay the rebound of HIV

Author: Zhou Zhou Release Date: 2018-10-09

Xinhua News Agency, Washington, October 7 The existing "antiretroviral therapy" cannot cure AIDS because HIV is "latent" in the "virus pool" of cells. US researchers have found that the combination of the two drugs is expected to delay the rebound of the virus after the "antiretroviral therapy" has stopped.

A recent study published in the journal Nature reported that the use of HIV-targeted antibodies in combination with innate immune system stimulators can delay or improve viral rebound in macaques.

The researchers infected 44 macaques with "SHIV," a virus that combines some of the "SIV" (monkey immunodeficiency virus) and "HIV" (human HIV) genomes, and began 130 weeks of antiretroviral transcription one week after infection. Virus treatment.

During the 130-week treatment period, the researchers divided the macaques into four groups. The first group was the control group and no other treatment was given. The second and third groups increased the "wide-neutralization antibody" and immunostimulant treatment after 96 weeks, respectively. The fourth group increased the combination of the two drugs after 96 weeks. .

Surveillance results after treatment showed that all control groups had a viral rebound and viral load peaked; almost all macaques treated with immunostimulants showed a viral rebound, while macaques treated with "widely neutralizing antibodies" had their viruses. There was a slight delay in rebound; among the 11 macaques treated with the combination of drugs, 5 had no virus rebound within 6 months after the end of antiretroviral therapy, and 6 macaques with virus rebound had a peak viral load. Below the control group.

Dan Baruch, the author of the paper and director of the Center for Virology and Vaccine Research at Beth Isrell's Deaconess Medical Center, said that the combination of the two drugs killed HIV-infected cells to the maximum extent. The library's potential treatment strategy provides preliminary theoretical verification.

Source: Xinhuanet

Biological Product For Human

Tetanus Toxoid Vaccine,Toxoid Vaccine,Hep B Immune Globulin,Immunoglobulin Injections

FOSHAN PHARMA CO., LTD. , https://www.fspharmamedicine.com